MiMedx Group (MDXG) Cantor Global Healthcare Conference 2025 summary

Market overview and business positioning

• Focus on wound and surgical healing solutions, addressing a large and growing patient population with chronic wounds, especially among Medicare beneficiaries.

• Products derived mainly from birth tissue, processed with proprietary technology, and protected by a robust IP portfolio.

• Vertically integrated operations with significant manufacturing headroom and a large direct sales force covering diverse care sites.

• Revenue split is approximately two-thirds wound care and one-third surgical, both segments showing strong growth.

• Strategic priorities center on expanding patient reach, business growth, and long-term shareholder value.

Regulatory and reimbursement environment

• Positive response to CMS's shift from ASP plus 6% to a flat price per square centimeter and application fee for reimbursement.

• Support for similar structural changes in the outpatient prospective payment system, with company comments to CMS expected to be largely supportive.

• Preparations underway for the new reimbursement model effective January, including product adjustments and readiness to scale manufacturing.

• Anticipation of a shift back to more reasonably priced products post-January 1, aligning with new reimbursement constraints.

Surgical business and innovation pipeline

• Surgical products initially used for clean closed incisions in compromised patients, now expanding to broader intraoperative applications.

• Portfolio includes amniotic tissue and xenograft products, with ongoing efforts to increase procedural relevance through internal development and M&A.

• Emphasis on generating clinical evidence to support product adoption across surgical disciplines.

• Recent presentations at major conferences and positive efficacy data for particulate products like HELIOGEN and AXIOFILL.

• Preference for partnerships or acquisitions to quickly expand into xenograft and synthetic technology verticals.